Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.
about
Adjuvants: Classification, Modus Operandi, and LicensingBeyond empiricism: informing vaccine development through innate immunity researchVaccines: the Fourth CenturyMucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in miceSafety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adultsAdjuvants for Leishmania vaccines: from models to clinical application.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyImmune response of hepatitis B vaccine among persons with diabetes: a systematic review of the literature.Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.Role of Toll-like receptors in liver health and disease.Current adjuvants and new perspectives in vaccine formulation.The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.Cancer vaccine adjuvants--recent clinical progress and future perspectives.Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.Developing vaccines for an aging population.Development of the CpG Adjuvant 1018: A Case Study.Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B.
P2860
Q26747586-641F9D25-F8F5-4323-9FD7-0AF7AB3E5792Q26824573-26FDD111-F81A-4C43-AAC6-64E615C3767BQ27490454-B85FE1C8-09B4-45D9-AF44-863DC432E09CQ34722855-EDCCF411-C201-438D-8994-23343004DE9EQ35878625-85BFEC04-AE74-47CC-BF34-0ED1CC04CF8DQ36021357-C91568FB-60F2-4C08-A6F4-300D97FE98E3Q36194849-13CAE8C1-E45A-404B-8F4D-56510AB7B52CQ36426868-655C4247-8BD5-42D0-8BF3-BC3E475A6042Q37069845-34417A16-6738-46B6-881F-1F6D5EC52AF3Q37867099-E5DA2ABA-6349-4164-AF93-685EB136DCA2Q37907346-EA242B17-F041-4C24-806A-14C68CE36D72Q37909424-E3CE3881-8CC3-4666-B46D-B3DAB40BCD52Q38111651-C4CA6C4B-BF7D-4526-8AC8-225F9553F2B7Q38260496-407AB872-9863-4CAF-9348-CAA46BCF54C7Q38270733-1D957E62-E633-4974-9365-992DBB4EF9F9Q38401015-C9AFEF98-17F4-4FC7-AFB2-807C0CD0CCD6Q40549653-5FA035D9-0660-4725-8444-5E66876137CEQ47553095-DF24D90F-E227-4E99-89EF-D6906DC46788
P2860
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Review of hepatitis B surface ...... g vaccine safety and efficacy.
@en
type
label
Review of hepatitis B surface ...... g vaccine safety and efficacy.
@en
prefLabel
Review of hepatitis B surface ...... g vaccine safety and efficacy.
@en
P2860
P1476
Review of hepatitis B surface ...... ng vaccine safety and efficacy
@en
P2093
Curtis Cooper
P2860
P304
P356
10.1517/14712598.7.11.1731
P407
P50
P577
2007-11-01T00:00:00Z